The European Medicine Agency's Committee for Medicinal Products for Human Use ("CHMP") is recommending that use of Eli ...
Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...
Eli Lilly's popular drug Mounjaro will be added to China's state-run health insurance scheme from January 1 for patients with ...
Eli Lilly and Company (NYSE:LLY) is one of the most profitable NYSE stocks to buy right now. In a report released on December ...
Investor's Business Daily on MSN
Eli Lilly Rises, Again, After EMA Groups Recommends Mounjaro For Children As Young As 10
On Friday, an EMA committee recommended extending the use of Eli Lilly's type 2 diabetes drug, Mounjaro, to children as young ...
The move broadens treatment choices for pediatric patients aged 10 years and older whose diabetes remains uncontrolled with ...
Dec 12 (Reuters) - The European Medicines Agency's committee on Friday recommended extending the use of Eli Lilly's ...
Abbott Laboratories (NYSE: ABT) and Eli Lilly (NYSE: LLY) just reported Q3 earnings that highlight two fundamentally ...
Eli Lilly's Mounjaro drug to be added to China's health insurance scheme for type 2 diabetes patients, potentially impacting ...
Eli Lilly’s weight loss drugs have delivered blockbuster sales in recent quarters. The company is a leader in this market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback